Publications Office of the EU
Norway-Oslo: Vaccines - EU tenders
DisplayCustomHeader
Procurement Detail Actions Portlet
OP Portal - Procurement - Details

Norway-Oslo: Vaccines

  • Awarded
    19/02/2014
  • Today
    06/09/2026
Status
Awarded
Type of contract
Supplies
Subject for Renewal
No
Buyer
Not available
Place of performance
NUTS code: Multiple place of performance
Location of buyer
NUTS code: Not available
Business sector (Main CPV)
33651600 Vaccines
Total estimated contract value (excluding VAT)
Not available
Total final contract value (excluding VAT)
4,335,520,043,355,200.00 NOK
Tender reference number
12/2131
Description

Open tender competition for purchase of combination vaccine again diptheria, tetanus, pertussis (acellular) and polio (dTP-polio) to booster vaccination to be used in the Norwegian child vaccination program.
The competition is carried out as an open competitive tender, a one step process where all interested suppliers may submit a tender. Negotiations are not allowed.

Submission Method
Not available
Tenders may be submitted
Not applicable
Information about a public contract, a framework agreement or a dynamic purchasing system (DPS)
Not available
Conditions for opening tenders (date)
Not available
Place of performance
Award method
The most economic tender
Estimated value
Not available
Final contracted value
4,335,520,043,355,200.00 NOK
Award of contract
Official name: GlaxoSmithKline AS
Postal address: Postboks 180, Vinderen
Town: Oslo
Postal code: 0319
Country: NOR
Prior information
Contract
Award
Footnote - legal notice

This content published on this page is meant purely as an additional service and has no legal effect. The Union's institutions do not assume any liability for its contents. The official versions of the relevant tendering notices are those published in the Supplement of Official Journal of the European Union and available in TED. Those official texts are directly accessible through the links embedded in this page. For more information please see Public Procurement Explainability and Liability notice.